Journal
MODERN RHEUMATOLOGY
Volume 19, Issue 1, Pages 69-72Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-008-0116-2
Keywords
Anti-IL-6 receptor antibody; Biologics; IL-6; Remission; AOSD
Categories
Funding
- Chugai Pharmaceutical Co., Ltd.
Ask authors/readers for more resources
Interleukin-6 overproduction is pathologically involved in adult onset Still's disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available